Strontium for Bone Health

Research suggests that strontium, particularly in the form of strontium ranelate, has demonstrated meaningful effects on bone health, with large Phase III clinical trials (SOTI and TROPOS) showing significant reductions in both vertebral and non-vertebral fracture risk in postmenopausal women, and reviews of trace mineral evidence supporting its role in stimulating bone formation pathways such as BMP-2 and Wnt/β-catenin signaling while inhibiting bone-resorbing cells. Studies in animal models further indicate that strontium supplementation improves bone mineral density and microarchitecture, with emerging research exploring its potential role in gut microbiome modulation and novel drug delivery systems for conditions like diabetic osteoporosis, and one study finding that combining strontium with teriparatide may produce additive benefits beyond either treatment alone. However, the evidence is not uniformly positive: a 2024 Australian clinical guideline has removed strontium ranelate as a recommended therapy, a narrative review flagged an increased risk of blood clots associated with strontium ranelate that limits its suitability to patients without cardiovascular risk factors, and a 2013 human evidence review characterized strontium's benefits for bone health in humans as still inconclusive. Additionally, research indicates that not all strontium formulations perform equally, with strontium citrate showing weaker effects than strontium ranelate or strontium chloride in animal models, and the broader body of evidence relies heavily on animal studies and mechanistic research rather than robust long-term human clinical trials.